What is Tirzepatide? Dual GLP-1/GIP Agonist Explained

You've heard the name — maybe from your doctor, maybe scrolling through headlines, maybe from a friend who's been on it for three months and won't stop talking about how different she feels. Tirzepatide is everywhere right now. But between the hype, the clinical jargon, and the sheer volume of opinions online, it's hard to know what this medication actually is and whether it's worth your attention.

We get it. At Amie, we believe you deserve to understand exactly what you're putting in your body — not just that something works, but why it works. So let's break this down clearly, honestly, and without the medical-textbook glaze.

By the end of this article, you'll understand what tirzepatide is, how its dual mechanism differs from other GLP-1 medications like semaglutide, what the clinical data actually shows, and what all of this means for your body — especially if you're a woman dealing with hormonal shifts, metabolic resistance, or the mental exhaustion of dieting. If you're new to this class of medications entirely, our GLP-1 Medications for Weight Loss: Complete Guide 2024 is a helpful starting point.

What Is Tirzepatide, Exactly?

The Plain-English Definition

Tirzepatide is a once-weekly injectable medication. Eli Lilly developed it and brought it to market under two brand names: Mounjaro, which the FDA approved in 2022 for type 2 diabetes management, and Zepbound, which received FDA approval in November 2023 specifically for chronic weight management.

It belongs to a class of drugs called incretin-based therapies — medications that mimic the natural gut hormones your body releases after you eat. But tirzepatide does something no previous medication in this class did: it activates two incretin hormone receptors instead of one.

Tirzepatide is prescribed for adults with type 2 diabetes (as Mounjaro) or for adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also have at least one weight-related health condition such as high blood pressure, dyslipidemia, or type 2 diabetes (as Zepbound). It is a prescription-only medication — you cannot get it over the counter or without a provider evaluation.

Where Does the Name Come From?

A small detail that reveals a lot: the "tir" in tirzepatide references the three peptide sequences fused together in its molecular structure. It's a single engineered molecule designed to do the work of two separate hormones. Eli Lilly filed its investigational new drug application, moved through Phase 3 clinical trials (the SURMOUNT program for weight loss, SURPASS for diabetes), and secured FDA approval in an unusually fast trajectory — a sign of how strong the clinical data was.

How Tirzepatide Works — The Dual GLP-1/GIP Mechanism Explained

This is where tirzepatide's story gets genuinely interesting — and where it separates itself from medications like semaglutide. Most articles stop at "it targets two receptors." Let's actually explain what that means in your body.

First, What Are Incretins?

Incretins are gut hormones your body releases after you eat. They send signals to your pancreas, your brain, and your digestive system — essentially telling your body: "Food just arrived. Let's process it."

Two incretins do most of the heavy lifting:

• GLP-1 (glucagon-like peptide-1) — the one you've likely heard of, since semaglutide (Ozempic, Wegovy) targets it
• GIP (glucose-dependent insulinotropic polypeptide) — the lesser-known partner, and the reason tirzepatide behaves differently

For a deeper look at how GLP-1 specifically affects women's bodies, see our guide on how GLP-1 agonists work for weight loss in women.

What the GLP-1 Pathway Does

When GLP-1 is activated — either naturally after a meal or by a medication like semaglutide or tirzepatide — several things happen:

• Gastric emptying slows down. Food moves through your stomach more slowly, so you stay full longer.
• Appetite signals in the brain decrease. GLP-1 receptors in the hypothalamus reduce hunger drive.
• Insulin release increases in response to blood sugar (glucose-dependent, meaning it works when needed).
• Glucagon gets suppressed — glucagon is a hormone that raises blood sugar, so dampening it helps with glucose control.

This is powerful on its own. Semaglutide proved that. But tirzepatide adds a second engine.

What the GIP Pathway Adds — The "Twincretin" Advantage

GIP is the incretin that doesn't get enough attention. Here's why it matters:

• GIP receptors exist not just in the pancreas, but in fat cells (adipose tissue), the brain, and bone
• GIP activation appears to enhance and amplify the effects of GLP-1 rather than simply adding a separate mechanism on top
• According to research published in Nature Reviews Endocrinology (2023), GIP receptor agonism may directly influence how fat cells store and release energy — meaning it affects body composition at the cellular level, not just appetite
• GIP may also reduce some of the GI side effects associated with GLP-1 therapy alone (particularly nausea), which helps explain why tolerability data for tirzepatide looks different than for semaglutide
• Early research suggests GIP receptor activation in the brain influences reward-based eating pathways — the circuits that drive cravings for high-fat, high-sugar foods

What This Means in Your Body, Day to Day

Clinical mechanisms are one thing. Lived experience is another. Women on dual-agonist incretin therapy consistently describe a few shifts that go beyond "eating less":

• Less mental preoccupation with food — that constant background noise of what should I eat, when should I eat, should I have eaten that gets quieter
• Feeling genuinely satisfied on smaller portions, without the white-knuckle willpower that comes with restrictive dieting
• Reduced cravings — particularly for highly palatable, high-sugar, high-fat foods
• More stable energy throughout the day, because blood sugar isn't spiking and crashing

Over weeks and months, these daily shifts compound into meaningful, sustained changes in weight and metabolic health — not the yo-yo pattern that crash diets create.

Tirzepatide vs. Other Weight Loss Medications — How Does It Compare?

One of the most common questions we hear: "Is tirzepatide better than semaglutide?" The honest answer is that "better" depends on your body, your medical history, your access, and your goals. But the clinical data does tell a clear story about differences. Here's how the major options stack up:

A few things stand out. Tirzepatide's dual-agonist mechanism produces the highest average weight loss in clinical trials. But there's a practical consideration: compounded versions of tirzepatide are not currently available the way compounded semaglutide is. That affects both cost and access. For a full breakdown, see our complete comparison guide to weight loss injections and our GLP-1 vs. traditional diet pills effectiveness review.

What the Clinical Trials Actually Show

The SURMOUNT Trial Program — Key Findings

Tirzepatide's weight loss data comes primarily from the SURMOUNT trial program. The numbers are worth knowing:

• SURMOUNT-1 (2022), published in the New England Journal of Medicine: Adults without diabetes lost up to 20.9% of their body weight over 72 weeks at the highest dose (15 mg). The placebo group lost 3.1%.
• SURMOUNT-2 (2023): Adults with type 2 diabetes lost up to 15.7% of body weight — still a striking result, since diabetes typically makes weight loss harder.
• For comparison, the STEP 1 trial for semaglutide (Wegovy) showed approximately 14.9% body weight loss at 68 weeks.

Beyond the Scale — Metabolic Markers That Matter

Weight loss is the headline number, but the metabolic improvements in these trials tell a deeper story:

• Significant reductions in HbA1c (a measure of long-term blood sugar control)
• Improvements in fasting insulin levels, triglycerides, and blood pressure
• The SURMOUNT-MMO trial (cardiovascular outcomes) is ongoing and expected to provide data on long-term heart health effects

According to findings published by Jastreboff et al. in NEJM (2022), tirzepatide's metabolic benefits extended well beyond glucose control — including meaningful improvements in cardiometabolic risk markers that disproportionately affect women after age 40.

Tirzepatide and Women's Health — What You Won't Read Elsewhere

Here's where we need to have a different conversation than what most medical sites offer. Women's metabolic biology is not a smaller version of men's. It's fundamentally different — and that difference matters when we talk about how medications like tirzepatide work.

Why Women's Metabolic Biology Makes This Conversation Different

Hormonal cycles, perimenopause, and menopause alter how the body stores fat, responds to appetite signals, and regulates insulin. Estrogen, specifically, plays a direct role in where fat is stored and how sensitive your cells are to insulin. When estrogen declines — as it does during perimenopause and menopause — visceral fat accumulation accelerates. This is the deep abdominal fat associated with higher cardiovascular and metabolic risk.

GLP-1 receptors interact with estrogen signaling pathways. Research on this interaction is still early, but it's one reason why incretin therapy may be particularly relevant for women in midlife — the hormonal window where weight becomes most resistant to diet and exercise alone.

Dual-agonist therapy like tirzepatide targets both appetite suppression (through GLP-1) and fat cell metabolism (through GIP) — which addresses the exact type of weight gain that hormonal shifts drive.

Body Composition, Not Just Weight Loss

The women who tend to feel best on GLP-1 therapy aren't just losing weight — they're maintaining or improving their lean muscle mass relative to fat mass. This matters because muscle loss during weight loss (sarcopenia) can actually worsen metabolic health long-term and accelerate aging.

Preserving lean mass requires intentional support: adequate protein intake (at least 1.0–1.2 grams per kilogram of body weight daily), consistent resistance training, and in some cases, additional peptide therapies. Two options our clinical team frequently discusses alongside GLP-1 programs are Sermorelin — a growth hormone-releasing peptide that supports lean mass preservation and recovery — and NAD+ therapy, which supports cellular energy and helps counter the metabolic fatigue some women experience during caloric restriction.

The Mental Load of Weight Loss

One of the most underreported effects of GLP-1/GIP therapy: the reduction in food noise. That's the clinical shorthand for the constant mental preoccupation with food — what to eat, what not to eat, guilt about eating, planning around eating, thinking about food when you're not hungry.

This is particularly meaningful for women. Research consistently shows that women carry a disproportionate cognitive burden around food, dieting, and body image — amplified by cultural messaging, caregiving roles, and the emotional labor of feeding a family.

GLP-1 receptors in the brain's reward system appear to quiet this noise. Tirzepatide's dual action — activating both GLP-1 and GIP receptors in the central nervous system — may amplify this effect. Women in our community describe it as "the first time food isn't running the show in my head." That's not a small thing. It's one of the most life-changing aspects of this class of medication.

Read about one woman's experience in our 6-month semaglutide case study.

How to Access Tirzepatide — And What to Consider

Who Is a Candidate for Tirzepatide?

The FDA-approved criteria for Zepbound (tirzepatide for weight management):

• BMI of 30 or greater (obesity), or
• BMI of 27 or greater (overweight) with at least one weight-related comorbidity — such as high blood pressure, type 2 diabetes, or high cholesterol
• Must be prescribed by a licensed healthcare provider after clinical evaluation

The Availability Challenge — Shortages and Cost

Tirzepatide has faced intermittent supply constraints since its launch. The brand-name cost is steep: approximately $1,000–$1,200 per month without insurance coverage. Insurance coverage is improving but remains inconsistent, especially for the weight management indication (Zepbound) vs. the diabetes indication (Mounjaro).

One critical difference from semaglutide: compounded tirzepatide is not widely available. The FDA's regulatory guidance on compounding for tirzepatide has been in flux, and the availability picture may change. As of this writing, semaglutide remains the incretin therapy with the broadest compounding access.

Starting Your GLP-1 Journey with Amie

Amie offers a telehealth-first approach to GLP-1 therapy: a thorough provider evaluation, a personalized treatment plan, and ongoing clinical support — no waiting rooms, no rushed appointments. Compounded semaglutide is available through Amie's platform for eligible patients.

The process is straightforward: complete your intake, connect with a licensed provider, and receive your prescription and care plan. Learn more about the full experience in our Amie telehealth review.

Frequently Asked Questions About Tirzepatide

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new medication. Individual results vary. Tirzepatide is a prescription medication with specific eligibility criteria and potential risks.

Author: Try Amie Editorial Team | Medical Review: Dr. Sarah Mitchell

Written by

Dr. Sarah Mitchell, MD

MD

Dr. Kim combines conventional medicine with holistic approaches to women's health. She specializes in menopause management, hormone balance, and longevity medicine.